atenolol has been researched along with Brain Vascular Disorders in 28 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nine hundred and thirty-nine patients with moderate to severe hypertension, observed for up to 10 years, were found to benefit from treatment with the beta1-selective agent atenolol (Tenormin), usually coprescribed with diuretics with or without vasodilators or other agents." | 7.68 | Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol). ( Cruickshank, JM, 1990) |
| "In persons aged 60 years and over with isolated systolic hypertension, antihypertensive stepped-care drug treatment with low-dose chlorthalidone as step 1 medication reduced the incidence of total stroke by 36%, with 5-year absolute benefit of 30 events per 1000 participants." | 5.07 | Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. ( , 1991) |
| "Nine hundred and thirty-nine patients with moderate to severe hypertension, observed for up to 10 years, were found to benefit from treatment with the beta1-selective agent atenolol (Tenormin), usually coprescribed with diuretics with or without vasodilators or other agents." | 3.68 | Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol). ( Cruickshank, JM, 1990) |
| "To investigate whether the lower the blood pressure (BP) the better the prognosis for the patient with moderate-to-severe hypertension, an assessment was made of 902 patients who received the beta 1-selective beta-blocker atenolol (median dose 100 mg a day), either alone or with other antihypertensive agents, for up to 10 years (mean 6." | 3.67 | Benefits and potential harm of lowering high blood pressure. ( Cruickshank, JM; Thorp, JM; Zacharias, FJ, 1987) |
| "1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8." | 2.69 | Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. ( , 1998) |
| "Captopril and atenolol were equally effective in reducing blood pressure to a mean of 144/83 mm Hg and 143/81 mm Hg respectively, with a similar proportion of patients (27% and 31%) requiring three or more antihypertensive treatments." | 2.69 | Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. ( , 1998) |
| "If atenolol was contraindicated, 0." | 2.67 | Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. ( Applegate, WB; Camel, GH; Greenlick, MR; Hadley, E; Luhr, J; Moye, L; Perry, HM; Pressel, S; Shekelle, RB; Wittes, J, 1994) |
| "Isolated systolic hypertension has a higher prevalence with age and an associated excess cardiovascular risk." | 2.67 | Conclusions and implications of the systolic hypertension in the elderly program. ( Davis, BR; Hawkins, CM; Moyé, LA; Probstfield, JL, 1993) |
| "The reduction in coronary disease is consistent with predictions based on prospective epidemiological studies and is concordant with other recent intervention trials." | 2.67 | Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group. ( , 1993) |
| "A randomised trial of the treatment of hypertension in 884 patients aged 60 to 79 years at the onset showed a reduction of 18/11 mm Hg in blood pressure over a mean follow up period of 4." | 2.66 | Randomised trial of treatment of hypertension in elderly patients in primary care. ( Coope, J; Warrender, TS, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (25.00) | 18.7374 |
| 1990's | 19 (67.86) | 18.2507 |
| 2000's | 2 (7.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Warmack, TS | 1 |
| Estes, MA | 1 |
| Heldenbrand, S | 1 |
| Franks, AM | 1 |
| de Boer, RA | 1 |
| van Veldhuisen, DJ | 1 |
| Gans, RO | 1 |
| Gansevoort, RT | 1 |
| Kappelle, LJ | 3 |
| van Latum, JC | 2 |
| van Swieten, JC | 2 |
| Algra, A | 3 |
| Koudstaal, PJ | 2 |
| van Gijn, J | 3 |
| Applegate, WB | 2 |
| Pressel, S | 1 |
| Wittes, J | 2 |
| Luhr, J | 1 |
| Shekelle, RB | 1 |
| Camel, GH | 1 |
| Greenlick, MR | 1 |
| Hadley, E | 1 |
| Moye, L | 1 |
| Perry, HM | 1 |
| Moyé, LA | 1 |
| Davis, BR | 3 |
| Hawkins, CM | 2 |
| Probstfield, JL | 2 |
| Cillessen, JP | 1 |
| Vogt, T | 1 |
| Frost, PH | 1 |
| Burlando, A | 1 |
| Cohen, J | 1 |
| Wilson, A | 1 |
| Brass, LM | 1 |
| Frishman, W | 1 |
| Price, T | 1 |
| Stamler, J | 1 |
| Black, HR | 1 |
| Elliott, WJ | 1 |
| Neaton, JD | 1 |
| Grandits, G | 1 |
| Grambsch, P | 1 |
| Grimm, RH | 1 |
| Hansson, L | 1 |
| Lacoucière, Y | 1 |
| Muller, J | 1 |
| Sleight, P | 1 |
| Weber, MA | 1 |
| White, WB | 1 |
| Williams, G | 1 |
| Zanchetti, A | 1 |
| Fakouhi, TD | 1 |
| Singer, RB | 1 |
| Pop, GA | 1 |
| Ménard, J | 1 |
| Chatellier, G | 1 |
| Petrovitch, H | 1 |
| Vogt, TM | 1 |
| Berge, KG | 1 |
| Coutard, M | 1 |
| Osborne-Pellegrin, M | 1 |
| Oppenheimer, SM | 1 |
| Cechetto, DF | 1 |
| Cruickshank, JM | 4 |
| Borhani, NO | 1 |
| Curb, JD | 1 |
| Cutler, JA | 1 |
| Furberg, CD | 1 |
| Lakatos, E | 1 |
| Page, LB | 1 |
| Thorp, JM | 2 |
| Zacharias, FJ | 2 |
| Coope, J | 1 |
| Warrender, TS | 1 |
| Barer, DH | 2 |
| Ebrahim, SB | 2 |
| Mitchell, JR | 2 |
| Higgins, TJ | 1 |
| Pennert, K | 1 |
| Zacharias, FM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000514] | Phase 3 | 0 participants | Interventional | 1984-06-30 | Completed | ||
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers[NCT03137966] | Phase 2 | 174 participants (Anticipated) | Interventional | 2022-12-30 | Not yet recruiting | ||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601] | Phase 3 | 170 participants | Interventional | 2005-02-28 | Completed | ||
| The Glooko Diabetes Mobile Monitoring and Management Advantage Study[NCT02974816] | 197 participants (Actual) | Interventional | 2017-05-15 | Completed | |||
| Propranolol as a Treatment for Impaired Awareness of Hypoglycemia in Type 1 Diabetes[NCT03161964] | Phase 2 | 2 participants (Actual) | Interventional | 2017-10-19 | Terminated (stopped due to Statistical power could not be achieved due to low enrollment.) | ||
| A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients[NCT04467879] | 146 participants (Actual) | Interventional | 2020-06-01 | Terminated (stopped due to New Protocol and Outcome Measures in Review) | |||
| Hypertension Management and Outcomes in a Family Practice Setting[NCT03579108] | 200 participants (Anticipated) | Observational | 2018-02-24 | Recruiting | |||
| Hypertension Prevalence, Treatment Patterns and Outcomes in Long-Term Care Facilities[NCT03046420] | 139 participants (Actual) | Observational | 2017-01-26 | Completed | |||
| Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients: A Prospective Randomized Open-Label Blinded-Endpoint Trial[NCT03015311] | 8,000 participants (Anticipated) | Interventional | 2017-01-15 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for atenolol and Brain Vascular Disorders
| Article | Year |
|---|---|
Beta-adrenergic antagonists in hypertension: a review of the evidence.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovasc | 2009 |
[Cooperative study of systolic arterial hypertension in the elderly patient (SHEP). Comments].
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Dis | 1992 |
Isolated systolic hypertension: lowering the risk of stroke in older patients. SHEP Cooperative Research Group.
Topics: Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Disease; Double-Blind Method; Hu | 1992 |
19 trials available for atenolol and Brain Vascular Disorders
| Article | Year |
|---|---|
Recurrent stroke after transient ischaemic attack or minor ischaemic stroke: does the distinction between small and large vessel disease remain true to type? Dutch TIA Trial Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebral Arteries; Cerebrovascular Disorders; Double-Blind Method; Female; | 1995 |
Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Atenolol; Cerebrovascular Disorders; Chlorthali | 1994 |
Conclusions and implications of the systolic hypertension in the elderly program.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cerebrovasc | 1993 |
Does cerebral infarction after a previous warning occur in the same vascular territory?
Topics: Aspirin; Atenolol; Basilar Artery; Carotid Arteries; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group.
Topics: Aged; Atenolol; Blood Pressure; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Transien | 1993 |
Implications of the systolic hypertension in the elderly program. The Systolic Hypertension in the Elderly Program Cooperative Research Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Cerebrovasc | 1993 |
Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Brain Ischemia; Cerebral Hemorrhage; Cerebr | 1998 |
Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Double- | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1998 |
Risk of cardiac events in atypical transient ischaemic attack or minor stroke. The Dutch TIA Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebrovascular Disorders; Death, Sudden, Cardiac; Diagnosis, Differential; | 1992 |
Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.
Topics: Aged; Amiloride; Atenolol; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Diu | 1992 |
Isolated systolic hypertension: lowering the risk of stroke in older patients. SHEP Cooperative Research Group.
Topics: Aged; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Coronary Disease; Double-Blind Method; Hu | 1992 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Cause of Death; Cerebrovascular Disorder | 1991 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Cerebrovascular Disorders; Chlorthalidone; Double-Blind Met | 1989 |
The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. The Dutch TIA Study Group.
Topics: Aspirin; Atenolol; Cerebrovascular Disorders; Disability Evaluation; Follow-Up Studies; Humans; Isch | 1988 |
Randomised trial of treatment of hypertension in elderly patients in primary care.
Topics: Aged; Atenolol; Bendroflumethiazide; Blood Pressure; Cerebrovascular Disorders; Clinical Trials as T | 1986 |
Low dose beta blockade in acute stroke ("BEST" trial): an evaluation.
Topics: Activities of Daily Living; Aged; Atenolol; Brain; Cerebrovascular Disorders; Clinical Trials as Top | 1988 |
The pragmatic approach to stroke trial design: stroke register, pilot trial, assessment of neurological then functional outcome.
Topics: Aged; Atenolol; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Method; Female; Hu | 1988 |
7 other studies available for atenolol and Brain Vascular Disorders
| Article | Year |
|---|---|
[Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agen | 2003 |
Stroke in the elderly treated for systolic hypertension (SHEP).
Topics: Actuarial Analysis; Age Factors; Aged; Aged, 80 and over; Atenolol; Cerebrovascular Disorders; Chlor | 1991 |
Rupture of the internal elastic lamina and vascular fragility in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Arteries; Atenolol; Blood Pressure; Capillary Fragility; Captopril; Cerebrovascular Disorde | 1991 |
Cardiac chronotropic organization of the rat insular cortex.
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Atropine; Cerebral Cortex; Cerebrovascular Disorders; Elect | 1990 |
Reduced total mortality and death from myocardial infarction and stroke in moderate/severe hypertensives treated with "Tenormin" (atenolol).
Topics: Atenolol; Blood Pressure; Cerebrovascular Disorders; Electrocardiography; Female; Humans; Hypertensi | 1990 |
Benefits and potential harm of lowering high blood pressure.
Topics: Adolescent; Adult; Age Factors; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cerebrovasc | 1987 |
The efficacy and tolerability of antihypertensive treatment based on atenolol in the prevention of stroke and the regression of left ventricular hypertrophy.
Topics: Adolescent; Adult; Aged; Atenolol; Blood Pressure; Cardiomyopathy, Hypertrophic; Cerebrovascular Dis | 1987 |